BioNTech (BNTX) Stock Price, News & Analysis

Company Overview

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics. Its most prominent commercial product is the COVID-19 vaccine BNT162b2, marketed as Comirnaty in collaboration with Pfizer, which received regulatory authorizations in multiple jurisdictions. Beyond that program, BioNTech maintains a diversified pipeline that includes individualized neoantigen cancer vaccines, T cell receptor (TCR) therapies, CAR-T candidates, and next-generation mRNA vaccine candidates for other infectious diseases such as influenza.

The company operates globally through research collaborations, strategic partnerships, and manufacturing agreements to support clinical trials and commercial supply. BioNTech has emphasized building internal manufacturing capabilities while also working with industry partners to scale production and distribution. Its research and development efforts involve collaborations with academic institutions, biotech and pharmaceutical companies to accelerate development timelines and broaden the reach of its platform technologies.

BioNTech was co-founded by Uğur Şahin and Özlem Türeci, who have been prominent figures in guiding the company's scientific and strategic direction; Şahin serves as Chief Executive Officer. The company continues to prioritize innovation in mRNA and cell-based immunotherapies, aiming to translate platform advances into approved medicines across multiple therapeutic areas while expanding its global research and commercial footprint.

Key Stats

• Today's Range: $87.75 to $89.95
• 50-Day Range: $85.25 to $111.60
• 52-Week Range: $79.52 to $124.00
• Volume: 837,172 shs
• Average Volume: 860,904 shs
• Market Capitalization: $22.27 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $129.56
• Consensus Rating: Moderate Buy

BioNTech Stock Analysis - MarketRank™

BioNTech scored higher than 74% of companies evaluated by MarketBeat, and ranked 193rd out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.74, and is based on 1 strong buy rating, 13 buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

BioNTech has a consensus price target of $129.56, representing about 47.1% upside from its current price of $88.08.

Amount of Analyst Coverage

BioNTech has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for BioNTech are expected to decrease in the coming year, from ($4.71) to ($4.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioNTech is -14.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioNTech is -14.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioNTech has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.20% of the float of BioNTech has been sold short.

Short Interest Ratio / Days to Cover

BioNTech has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioNTech has recently increased by 10.73%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

BioNTech does not currently pay a dividend.

Dividend Growth

BioNTech does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.46

News Sentiment

BioNTech has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for BioNTech this week, compared to 7 articles on an average week.

Search Interest

Only 11 people have searched for BNTX on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.

MarketBeat Follows

5 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, BioNTech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,528,000.00 in company stock.

Percentage Held by Insiders

19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

15.52% of the stock of BioNTech is held by institutions.

Company Calendar

• Last Earnings: 2/14/2026
• Today: 6/05/2026
• Next Earnings (Estimated): 8/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BNTX
• CIK: 1776985
• Web: www.biontech.de
• Phone: 49-61-31908-40
• Fax: 49-6131-908-4390
• Employees: 7,807
• Year Founded: 2008

Price Target and Rating

• Average Price Target for BioNTech: $129.56
• High Price Target: $158.00
• Low Price Target: $94.00
• Potential Upside/Downside: +47.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.74
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.29 billion
• Net Margins: -44.39%
• Pretax Margin: -42.39%
• Return on Equity: -5.30%
• Return on Assets: -4.62%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 8.80
• Quick Ratio: 8.74

Sales & Book Value

• Annual Sales: $3.25 billion
• Price / Sales: 6.86
• Cash Flow: $1.31 per share
• Price / Cash Flow: 67.10
• Book Value: $96.59 per share
• Price / Book: 0.91

Miscellaneous

• Outstanding Shares: 252,880,000
• Free Float: 204,330,000
• Market Cap: $22.27 billion
• Optionable: Optionable
• Beta: 1.32